Plasma visfatin levels are associated with major adverse cardiovascular events in patients with acute ST-elevation myocardial infarction

Clinical and Investigative Medicine

Volumn 38, Issue 3, 2015, Pages E100-E109

  Hung, Wei Chin ^a   Yu, Teng Hung ^a   Hsu, Chia Chang ^a   Lu, Li Fen ^a   Chung, Fu Mei ^a   Tsai, I Ting ^a   Lu, Yung Chuan ^a   Houng, Jer Yiing ^a   Lee, Yau Jiunn ^b   Wang, Chao Ping ^a  

^a I SHOU UNIVERSITY   (Taiwan)

^b Lee's Endocrinologic Clinic   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE;

AGED; BLOOD; COMPLICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HEART INFARCTION; HUMAN; MALE; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK FACTOR;

AGED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84930393232     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-874.
2. Schroeder AP, Falk E. Pathophysiology and inflammatory aspects of plaque. Rupture. Cardiol Clin. 1996;14:211-220.
3. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem. 2008;54:24-38.
4. Arner P. Insulin resistance in type 2 diabetes-role of the adipokines. Curr Mol Med. 2005;5:333-339.
5. Matsuzawa Y. White adipose tissue and cardiovascular disease. Best Pract Res Clin Endocrinol Metab. 2005;19:637-647.
6. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005;115:911-919.
7. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony- enhancing factor. Mol Cell Biol. 1994;14:1431-1437.
8. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307:426-430.
9. Cheng KH, Chu CS, Lee KT, Lin TH, Hsieh CC, Chiu CC, Voon WC, Sheu SH, Lai WT. Adipocytokines and proinflammatory mediators from abdominal and epicardial adipose tissue in patients with coronary artery disease. Int J Obes. 2008;32:268-274.
10. Tanaka M, Nozaki M, Fukuhara A, Segawa K, Aoki N, Matsuda M, Komuro R, Shimomura I. Visfatin is released from 3T3-L1 adipocytes via a non-classical pathway. Biochem Biophys Res Commun. 2007;359:194- 201.
11. Liu SW, Qiao SB, Yuan JS, Liu DQ. Association of plasma visfatin levels with inflammation, atherosclerosis, and acute coronary syndromes (ACS) in humans. Clin Endocrinol. 2009;71:202-207.
12. Dahl TB, Yndestad A, Skjelland M, Øie E, Dahl A, Michelsen A, Damås JK, Tunheim SH, Ueland T, Smith C, Bendz B, Tonstad S, Gullestad L, Frøland SS, Krohg-Sørensen K, Russell D, Aukrust P, Halvorsen B. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis:possible role in inflammation and plaque destabilization. Circulation. 2007;115:972-980.
13. Cirillo P, Di Palma V, Maresca F, Pacifico F, Ziviello F, Bevilacqua M, Trimarco B, Leonardi A, Chiariello M. The adipokine visfatin induces tissue factor expression in human coronary artery endothelial cells: Another piece in the adipokines puzzle. Thromb Res. 2012;130:403-408.
14. Yu TH, Lu LF, Hung WC, Chiu CA, Liu YT, Yang CY, Tsai IT, Yen YC, Chen CY, Wang CP. Circulating visfatin level at admission is associated with occlusion of the infarct-related artery in patients with acute ST-segment elevation myocardial infarction. Acta Cardiologica Sinica. 2011;27:77-85.
15. Lu LF, Wang CP, Yu TH, Hung WC, Chiu CA, Chung FM, Tsai IT, Yang CY, Cheng YA, Lee YJ, Yeh LR. Interpretation of elevated plasma visfatin concentrations in patients with STelevation myocardial infarction. Cytokine. 2012;57:74-80.
16. Mazaherioun M, Hosseinzadeh-Attar MJ, Janani L, Vasheghani Farahani A, Rezvan N, Karbaschian Z, Hossein-Nezhad A. Elevated serum visfatin levels in patients with acute myocardial infarction. Arch Iran Med. 2012;15:688-692.
17. Zhong M, Tan HW, Gong HP, Wang SF, Zhang Y, Zhang W. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol. 2008;69:878-884.
18. Chung FM, Tsai JC, Chang DM, Shin SJ, Lee YJ. Peripheral total and differential leukocyte count in diabetic nephropathy:the relationship of plasma leptin to leukocytosis. Diabetes Care. 2005;28:1710-1717.
19. Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, Lee YJ. Elevated plasma level of visfatin/pre-B cell colonyenhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2006;91:295-299.
20. Deedwania P, Kosiborod M, Barrett E, Ceriello A, Isley W, Mazzone T, Raskin P. American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism, Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2008;117:1610-1619.
21. K/DOQI clinical practice guidelines for chronic kidney disease:evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39:S1-S266.
22. Gao Y, Tong GX, Zhang XW, Leng JH, Jin JF, Wang NF, Yang JM. Interleukin-18 levels on admission are associated with midterm adverse clinical events in patients with ST-segment elevation acute myocardial infarction undergoing percutaneous coronary intervention. Int Heart J. 2010;51:75-81.
23. van der Veer E, Nong Z, O'Neil C, Urquhart B, Freeman D, Pickering JG. Pre-B-cell colony-enhancing factor regulates NAD+-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation. Circ Res. 2005;97:25-34.
24. McGlothlin JR, Gao L, Lavoie T, Simon BA, Easley RB, Ma SF, Rumala BB, Garcia JG, Ye SQ. Molecular cloning and characterization of canine pre-B-cell colonyenhancing factor. Biochem Genet Apr. 2005;43:127-141.
25. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, Tilg H. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol. 2007;178:1748-1758.
26. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90:251-262.
27. Chiu CA, Yu TH, Hung WC, Lu LF, Chung FM, Tsai IT, Yang CY, Hsu CC, Lu YC, Houng JY, Lee YJ, Wang CP. Increased expression of visfatin in monocytes and macrophages in male acute myocardial infarction patients. Mediators Inflamm. 2012;2012:469852.
28. Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism. 2007;56:451-458.
29. Romacho T, Azcutia V, Vázquez-Bella M, Matesanz N, Cercas E, Nevado J, Carraro R, Rodríguez-Mañas L, Sánchez-Ferrer CF, Peiró C. Extracellular PBEF/NAMPT/ visfatin activates proinflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia. 2009;52:2455-2463.
30. Adya R, Tan BK, Punn A, Chen J, Randeva HS. Visfatin induces human endothelial VEGF and MMP/2/9 production via MAPK and PI3K/Akt signalling pathway: novel insights into visfatin-induced angiogenesis. Cardiovasc Res. 2008;78:356-365.
31. Saddi-Rosa P, Oliveira C, Crispim F, Giuffrida FM, de Lima V, Vieira J, Doria A, Velho G, Reis A. Association of circulating levels of nicotinamide phosphoribosyltransferase (NAMPT/ Visfatin) and of a frequent polymorphism in the promoter of the NAMPT gene with coronary artery disease in diabetic and nondiabetic subjects. Cardiovasc Diabetol. 2013;12:119.
32. Lu LF, Yang SS, Wang CP, Hung WC, Yu TH, Chiu CA, Chung FM, Shin SJ, Lee YJ. Elevated visfatin/pre-B-cell colonyenhancing factor plasma concentration in ischemic stroke. J Stroke Cerebrovasc Dis. 2009;18:354-359.
33. Kadoglou NP, Fotiadis G, Lambadiari V, Maratou E, Dimitriadis G, Liapis CD. Serum levels of novel adipokines in patients with acute ischemic stroke: potential contribution to diagnosis and prognosis. Peptides. 2014;57:12-16.
34. Grzywocz P, Mizia-Stec K, Wybraniec M, Chudek J. Adipokines and endothelial dysfunction in acute myocardial infarction and the risk of recurrent cardiovascular events. J Cardiovasc Med (Hagerstown). 2015;16:37-44.
35. Pusuroglu H, Akgul O, Cakmak HA, Erturk M, Surgit O, Celik O, Ozturk D, Uzun F, Akkaya E, Yildirim A. Long-term prognostic value of admission haemoglobin A1c (HbA1c) levels in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Postepy Kardiol Interwencyjnej. 2014;10:166-174.
36. Tomey MI, Mehran R, Brener SJ, Maehara A, Witzenbichler B, Dizon JM, El-Omar M, Xu K, Gibson CM, Stone GW. Sex, adverse cardiac events, and infarct size in anterior myocardial infarction: an analysis of intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction (INFUSE-AMI). Am Heart J. 2015;169:86-93.